Levofloxacin plus aminoglycoside superior to ciprofloxacin after prostate biopsy
the ONA take:
This study investigated the potential benefit of oral fluoroquinolone prophylaxis in patients undergoing transrectal ultrasound-guided (TUG) prostate biopsy.
The researchers compared two prophylactic antibiotic regimens: one dose of ciprofloxacin 500 mg combined with an aminoglycoside (AG) or one dose of levofloxacin 750 mg combined with an AG.
The ciprofloxacin group involved 535 biopsies, and the levofloxacin 654 biopsies. Total infection rate was 3.18% in the ciprofloxacin group and 2.14% in the levofloxacin group.
The rate of mild infection was 0.75% in the ciprofloxacin group and 1.22% in the levofloxacin group; however, the rate of severe infection was higher in the ciprofloxacin group compared with the levofloxacin group (2.43% vs 0.92%, respectively).
Use of a single dose of fluoroquinolone augmented with an AG is optimal prophylaxis to reduce infectious complications in patients undergoing prostate biopsy.
The researchers found that 750 mg levofloxacin is more effective than 500 mg ciprofloxacin in reducing severe infections in these patients.
Use of single dose of fluoroquinoloneis optimal prophylaxis to reduce infectious complications in patients undergoing prostate biopsy.
Sign Up for Free e-newsletters
- Incidence of Post-traumatic Stress Disorder High Among Patients With Cancer
- Long-Term Night Shift Work Associated With Cancer Risk in Women
- Distress, Neuroticism Predict Long-term Emotional Distress After Cancer Diagnosis
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- FDA Grants Breakthrough Therapy Designation to Lenvatinib Plus Pembrolizumab for RCC
- Bacteria in Probiotics Carry Potential Risks for Immunocompromised Patients
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Breast Cancer Deaths Decrease Sharply Since 2000
- Identifying the Psychosocial Needs of Young Adults With Metastatic Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|